Glycolysis Define Two Prognostic Subgroups of Lung Adenocarcinoma With Different Mutation Characteristics and Immune Infiltration Signatures

被引:4
|
作者
Huo, Chen [1 ]
Zhang, Meng-Yu [1 ]
Li, Rui [1 ]
Liu, Ting-Ting [1 ]
Li, Jian-Ping [1 ]
Qu, Yi-Qing [2 ]
机构
[1] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Pulm & Crit Care Med,Shandong Key Lab Infect, Jinan, Peoples R China
[2] Shandong Univ, Qilu Hosp, Dept Pulm & Crit Care Med, Shandong Key Lab Infect Resp Dis, Jinan, Peoples R China
关键词
lung adenocarcinoma; glycolysis; tumor mutational burdens; prognosis; tumor-infiltrating immune cell; INTERACTION NETWORKS; CANCER; TUMORS; INHIBITION; RESISTANCE;
D O I
10.3389/fcell.2021.645482
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Increasing studies have proved that malignant tumors are associated with energy metabolism. This study was aimed to explore biological variables that impact the prognosis of patients in the glycolysis-related subgroups of lung adenocarcinoma (LUAD). The mRNA expression profiling and mutation data in large LUAD samples were collected from the Cancer Genome Atlas (TCGA) database. Then, we identified the expression level and prognostic value of glycolysis-related genes, as well as the fractions of 22 immune cells in the tumor microenvironment. The differences between glycolysis activity, mutation, and immune infiltrates were discussed in these groups, respectively. Two hundred fifty-five glycolysis-related genes were identified from gene set enrichment analysis (GSEA), of which 43 genes had prognostic values (p < 0.05). Next, we constructed a glycolysis-related competing endogenous RNA (ceRNA) network which related to the survival of LUAD. Then, two subgroups of LUAD (clusters 1 and 2) were identified by applying unsupervised consensus clustering to 43 glycolysis-related genes. The survival analysis showed that the cluster 1 patients had a worse prognosis (p < 0.001), and upregulated differentially expressed genes (DEGs) are interestingly enriched in malignancy-related biological processes. The differences between the two subgroups are SPTA1, KEAP1, USH2A, and KRAS among top 10 mutated signatures, which may be the underlying mechanism of grouping. Combined high tumor mutational burden (TMB) with tumor subgroups preferably predicts the prognosis of LUAD patients. The CIBERSORT algorithm results revealed that low TMB samples were concerned with increased infiltration level of memory resting CD4+ T cell (p = 0.03), resting mast cells (p = 0.044), and neutrophils (p = 0.002) in cluster 1 and high TMB samples were concerned with increased infiltration level of memory B cells, plasma cells, CD4 memory-activated T cells, macrophages M1, and activated mast cells in cluster 2, while reduced infiltration of monocytes, resting dendritic cells, and resting mast cells was captured in cluster 2. In conclusion, significant different gene expression characteristics were pooled according to the two subgroups of LUAD. The combination of subgroups, TMB and tumor-infiltrating immune cell signature, might be a novel prognostic biomarker in LUAD.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Identification of fatty acid-related subtypes, the establishment of a prognostic signature, and immune infiltration characteristics in lung adenocarcinoma
    Wang, Yuzhi
    Huang, Xiaoxiao
    Fan, Hong
    Xu, Yunfei
    Qi, Zelin
    Zhang, Yi
    Huang, Yi
    AGING-US, 2023, 15 (10): : 4202 - 4235
  • [22] Four drug metabolism-related subgroups of pancreatic adenocarcinoma in prognosis, immune infiltration, and gene mutation
    Zhang, Tongyi
    Zhu, Liyong
    Cai, Jianhua
    He, Jiaqi
    OPEN MEDICINE, 2022, 17 (01): : 427 - 440
  • [23] Lung immune signatures define two groups of end-stage IPF patients
    Cruz, Tamara
    Mendoza, Nuria
    Casas-Recasens, Sandra
    Noell, Guillaume
    Hernandez-Gonzalez, Fernanda
    Frino-Garcia, Alejandro
    Alsina-Restoy, Xavi
    Molina, Maria
    Rojas, Mauricio
    Agusti, Alvar
    Sellares, Jacobo
    Faner, Rosa
    RESPIRATORY RESEARCH, 2023, 24 (01)
  • [24] Lung immune signatures define two groups of end-stage IPF patients
    Tamara Cruz
    Núria Mendoza
    Sandra Casas-Recasens
    Guillaume Noell
    Fernanda Hernandez-Gonzalez
    Alejandro Frino-Garcia
    Xavi Alsina-Restoy
    María Molina
    Mauricio Rojas
    Alvar Agustí
    Jacobo Sellares
    Rosa Faner
    Respiratory Research, 24
  • [25] Pregnancy Zone Protein Serves as a Prognostic Marker and Favors Immune Infiltration in Lung Adenocarcinoma
    Chen, Kehong
    Zheng, Taihao
    Chen, Cai
    Liu, Liangzhong
    Guo, Zhengjun
    Peng, Yuan
    Zhang, Xiaoyue
    Yang, Zhenzhou
    BIOMEDICINES, 2023, 11 (07)
  • [26] PCM1: A Potential Prognostic Biomarker Correlated with Immune Infiltration in Lung Adenocarcinoma
    Guo, Zhihua
    Liang, Jinghao
    Zhang, Xin
    Ai, Qing
    Xie, Zixian
    Zhao, Haonan
    Wu, Fayuan
    Tan, Zhaofeng
    Yin, Weiqiang
    Ji, Linghua
    CURRENT PROTEOMICS, 2023, 20 (03) : 208 - 221
  • [27] Identification of prognostic candidate signatures by systematically revealing transcriptome characteristics in lung adenocarcinoma with differing tumor microenvironment immune phenotypes
    Chen, Qiang
    Ma, Jiakang
    Wang, Xiaoyi
    Zhu, Xiangqing
    AGING-US, 2022, 14 (11): : 4786 - 4818
  • [28] Identification of subgroups and development of prognostic risk models along the glycolysis-cholesterol synthesis axis in lung adenocarcinoma
    Jiang, Jiuzhou
    Qian, Bao
    Guo, Yangjie
    He, Zhengfu
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [29] BDNF is a prognostic biomarker involved in immune infiltration of lung adenocarcinoma and is associated with brain metastasis
    Yu, Qian
    Wang, Yitian
    Yi, Guangming
    Yang, Wendi
    Chen, Kehong
    Tan, Xiangwu
    Zhang, Xiaoyue
    Xu, Zaicheng
    Yang, Zhenzhou
    Peng, Yuan
    IMMUNOLOGY, 2023, 168 (02) : 320 - 330
  • [30] TYK2 is a prognostic biomarker and associated with immune infiltration in the lung adenocarcinoma microenvironment
    He, Aoxiao
    Zhang, Rongguiyi
    Wang, Jiakun
    Huang, Zhihao
    Liao, Wenjun
    Li, Yong
    Wang, Cong
    Yang, Jun
    Feng, Qian
    Wu, Linquan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (02) : E129 - E140